Wednesday, March 21, 2018 9:09:55 AM
Company is preparing for efficacy experiments in mice
SAN DIEGO, March 21, 2018 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP) and (OTCQB: RGBPP) has been methodically optimizing small molecules that bind to, and activate, the NR2F6 nuclear receptor. The process is close to completion, with the primary and back up compounds being readied for final pre-clinical mouse experiments.
"We are currently preparing to test these compounds in different mouse models of autoimmunity. The final dosing experiments should be completed shortly and then we can move into efficacy studies in mice," says Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen.
"Having an optimized lead candidate is the culmination of a great deal of strategic planning and scientific work," says David Koos, Ph.D., Chairman & CEO Regen BioPharma Inc., "I am gratified that we are so close to achieving this important milestone and look forward to the next phase of drug development."
The NR2F6 nuclear receptor has been identified as a potentially very important immune cell inhibitor (an immune checkpoint) and cancer stem cell differentiator. The NR2F6 program at Regen aims to identify antagonists of NR2F6 in an effort to unleash the cancer-killing potential of a patient's own immune system as well as identifying agonists which should suppress the immune system in diseases where the immune system is over-activated, such as autoimmunity.
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM